2024 continues to be a tricky year for German biotech Evotec SE, as difficult market conditions hamper its turnaround endeavors. It now plans cut around 400 jobs, exit gene therapy and close its site in Orth, Austria, as it redoubles its reorganization efforts.
“The market environment has given us no new signals of recovery to happen still within 2024 as we hoped for....





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
